News Release

Pfizer-BioNTech vaccine in patients undergoing cancer treatment

JAMA Oncology

Peer-Reviewed Publication

JAMA Network

What The Study Did: The SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine appeared to be safe and achieve satisfactory serologic status in patients with cancer. While there was a lag in antibody production compared with the rate in the noncancer control group, seroconversion occurred in most patients after the second dose.

Authors: Irit Ben-Aharon, M.D., Ph.D., of the Rambam Health Care Campus in Haifa, Israel, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.


Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.